["Yao, K. et al. (2025). Aripiprazole alleviates the high prolactin levels induced by amisulpride via distinct molecular mechanisms: a network pharmacology and molecular docking study.", "Yu, J. et al. (2025). Transcriptomic analysis and experiment to verify the mechanism of Xiaoyao san in the treatment of irritable bowel syndrome with depression.", "Su, T. et al. (2025). The dopamine receptor agonist rotigotine attenuated indomethacin-induced enteropathy in the small intestinal mucosa of mice.", "Olasore, H. et al. (2025). Dopamine receptor D2 (DRD2) TaqIA gene polymorphism and acute risperidone-induced changes in body weight, plasma glucose and lipid profile.", "Muhetaer, H. et al. (2025). Exploring the Effects and Mechanisms of Valerian Volatile Oil in Treating Insomnia Using Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation-Based Approaches.", "Sharo, C. et al. (2024). Repurposing FDA-Approved Drugs Against Potential Drug Targets Involved in Brain Inflammation Contributing to Alzheimer's Disease.", "Wojcieszak, J. et al. (2025). Access to high-fat diet results in increased sensitivity to the psychostimulant effects of MDPV in mice.", "Pearson, A. et al. (2025). Paediatric strategy forum for medicinal product development in diffuse midline gliomas in children and adolescents ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.", "Fidry, M. et al. (2024). Pharmacogenetic Testing in Treatment-resistant Panic Disorder: a Preliminary Analysis.", "Kinoshita, I. et al. (2025). Co-Expression of Tardive Dyskinesia and Drug-Induced Parkinsonism in Rats Chronically Treated With Haloperidol.", "Kovaleva, K. et al. (2024). GENETIC VARIANTS IN ANTIPSYCHOTIC METABOLISM: POLYMORPHISM PROFILES IN KAZAKH COHORT WITH PARANOID SCHIZOPHRENIA.", "Li, S. et al. (2024). The Activation of p300 Enhances the Sensitivity of Pituitary Adenomas to Dopamine Agonist Treatment by Regulating the Transcription of DRD2.", "Ma, S. et al. (2024). Role of ruscogenin extracted from Radix Ophiopogon Japonicus in antagonizing 5-hydroxytryptamine and dopamine receptors through computational screening.", "Low, J. et al. (2024). Genetic susceptibility to caffeine intake and metabolism: a systematic review.", "Beer, F. et al. (2024). Antipsychotic dopamine D(2) affinity and negative symptoms in remitted first episode psychosis patients.", "Annis, A. et al. (2025). Genetic Associations of Persistent Opioid Use After Surgery Point to OPRM1 but Not Other Opioid-Related Loci as the Main Driver of Opioid Use Disorder.", "Lambert, J. et al. (2024). Association of genetic variants in CYP3A5, DRD2 and NK1R with opioid overdose.", "Luo, T. et al. (2024). Network pharmacology screening, in vitro and in vivo evaluation of antianxiety and antidepressant drug-food analogue.", "Qu, K. et al. (2024). Association Study Between DRD2, DRD3 Genetic Polymorphisms and Adverse Reactions in Chinese Patients on Amisulpride Treatment.", "Zhang, Y. et al. (2024). Recent Advances in representative small-molecule DRD2 inhibitors: Synthetic Routes and clinical applications.", "Devincci, A. et al. (2025). Longitudinal sex-specific impacts of high-fat diet on dopaminergic dysregulation and behavior from periadolescence to late adulthood.", "Mathis, T. et al. (2024). DRD2 activation inhibits choroidal neovascularization in patients with Parkinson's disease and age-related macular degeneration.", "Heidari, A. et al. (2024). Parental Exposure to Morphine Before Conception Decreases Morphine and Cocaine-Induced Locomotor Sensitization in Male Offspring.", "Li, Y. et al. (2024). Chronic pharmacologic manipulation of dopamine transmission ameliorates metabolic disturbance in Trappc9-linked brain developmental syndrome.", "Lewandrowski, K. et al. (2024). A Pharmacogenomics-Based In Silico Investigation of Opioid Prescribing in Post-operative Spine Pain Management and Personalized Therapy.", "Adejare, A. et al. (2023). Brain antioxidant status and gene expressions of nicotinic and dopamine receptors are improved by black seed oil administration in cigarette smoke or nicotine vapour-exposed rats.", "Muro, G. et al. (2024). The Novel SSTR3 Agonist ITF2984 Exerts Antimitotic and Proapoptotic Effects in Human Non-Functioning Pituitary Neuroendocrine Tumor (NF-PitNET) Cells.", "Basu, A. et al. (2024). Pharmacogenomics-assisted schizophrenia management: A hybrid type 2 effectiveness-implementation study protocol to compare the clinical utility, cost-effectiveness, and barriers.", "Sanguesa, E. et al. (2024). Impact of Pharmacogenetic Testing on Clozapine Treatment Efficacy in Patients with Treatment-Resistant Schizophrenia.", "Li, C. et al. (2024). Molecular mechanisms of quetiapine bidirectional regulation of bipolar depression and mania based on network pharmacology and molecular docking: Evidence from computational biology.", "Shilbayeh, S. et al. (2024). The polymorphisms of candidate pharmacokinetic and pharmacodynamic genes and their pharmacogenetic impacts on the effectiveness of risperidone maintenance therapy among Saudi children with autism.", "Li, H. et al. (2024). Vitamin D3 improves iminodipropionitrile-induced tic-like behavior in rats through regulation of GDNF/c-Ret signaling activity.", "Bertotto, L. et al. (2024). Effects of the Phosphodiesterase 10A Inhibitor MR1916 on Alcohol Self-Administration and Striatal Gene Expression in Post-Chronic Intermittent Ethanol-Exposed Rats.", "Odia, Y. et al. (2024). Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.", "Biswas, M. et al. (2023). Pharmacogenomics and non-genetic factors affecting drug response in autism spectrum disorder in Thai and other populations: current evidence and future implications.", "Liu, Y. et al. (2024). Reviving: restoring depression-like behaviour through glial cell-derived neurotrophic factor treatment in the medial prefrontal cortex.", "Arai, M. et al. (2024). Enhancement of Haloperidol-Induced Catalepsy by GPR143, an L-Dopa Receptor, in Striatal Cholinergic Interneurons.", "Schuster, J. et al. (2024). In-depth analysis of data from the RAS-ALS study reveals new insights in rasagiline treatment for amyotrophic lateral sclerosis.", "Starkiewicz, A. et al. (2024). Identification of genes regulated by trait sensitivity to negative feedback and prolonged alcohol consumption in rats.", "Wong, A. et al. (2023). Effect of gene variants on opioid dose, pain and adverse effect outcomes in advanced cancer: an explorative study.", "Lakshmi, Y. et al. (2023). Unravelling the Molecular Mechanisms of a Quercetin Nanocrystal for Treating Potential Parkinson's Disease in a Rotenone Model: Supporting Evidence of Network Pharmacology and In Silico Data Analysis.", "Taheri, N. et al. (2023). Association of DRD2, DRD4 and COMT genes variants and their gene-gene interactions with antipsychotic treatment response in patients with schizophrenia.", "Docherty, A. et al. (2023). GWAS Meta-Analysis of Suicide Attempt: Identification of 12 Genome-Wide Significant Loci and Implication of Genetic Risks for Specific Health Factors.", "Gao, Z. et al. (2023). Potential effect of antidepressants on remission from cocaine use disorder - A nationwide matched retrospective cohort study.", "Moon, J. et al. (2024). Possible genetic biomarker associated with antipsychotic-induced amenorrhea in female patients with schizophrenia.", "Wang, Y. et al. (2023). Chronic stress accelerates glioblastoma progression via DRD2/ERK/beta-catenin axis and Dopamine/ERK/TH positive feedback loop.", "Tanrikulu, B. et al. (2023). Preliminary findings of German-sourced ONC201 treatment in H3K27 altered pediatric pontine diffuse midline gliomas.", "Qin, Y. et al. (2024). DRD2 TaqIA polymorphism-related functional connectivity between anterior insula and dorsolateral prefrontal cortex predicts the retention time in heroin-dependent individuals under methadone maintenance treatment.", "Pan, B. et al. (2023). Integrative multilevel exploration of the mechanism by which Er-Zhi-Wan alleviates the Parkinson's disease (PD)-like phenotype in the MPTP-induced PD mouse model.", "Shi, L. et al. (2023). The DRD2 Antagonist Haloperidol Mediates Autophagy-Induced Ferroptosis to Increase Temozolomide Sensitivity by Promoting Endoplasmic Reticulum Stress in Glioblastoma.", "Pieri, M. et al. (2023). Functional single nucleotide polymorphisms in dopaminergic receptors D2 predict clinical response to Cariprazine.", "Wieting, J. et al. (2023). Hypomethylation of the dopamine transporter (DAT) gene promoter is associated with hyperphagia-related behavior in Prader-Willi syndrome: A case-control study.", "Ahlstrom, S. et al. (2023). Clinical and genetic factors associated with post-operative nausea and vomiting after propofol anaesthesia.", "Cheng, Y. et al. (2023). Multi-trait genome-wide association analyses leveraging alcohol use disorder findings identify novel loci for smoking behaviors in the Million Veteran Program.", "Wang, Z. et al. (2023). Peony-Glycyrrhiza Decoction for Antipsychotic-Related Hyperprolactinemia in Patients with Schizophrenia: A Randomized Controlled Trial.", "Rochowiak, E. et al. (2022). Studies on candidate genes for lithium prophylaxis performed at the Poznan University of Medical Sciences.", "Teng, Y. et al. (2023). The Progress and Pitfalls of Pharmacogenetics-Based Precision Medicine in Schizophrenia Spectrum Disorders: A Systematic Review and Meta-Analysis.", "Ying, J. et al. (2023). Treatment-Resistant Schizophrenia, Clozapine Resistance, Genetic Associations, and Implications for Precision Psychiatry: A Scoping Review.", "Nasyrova, R. et al. (2023). Single-Nucleotide Polymorphisms as Biomarkers of Antipsychotic-Induced Akathisia: Systematic Review.", "Jeon, H. et al. (2023). Dopamine receptor D2 regulates glioblastoma survival and death through MET and death receptor 4/5.", "Loureiro, C. et al. (2023). Lifetime cannabis use and childhood trauma associated with CNR1 genetic variants increase the risk of psychosis: findings from the STREAM study.", "Liang, Y. et al. (2023). Study on Anti-Constipation Effects of Hemerocallis citrina Baroni through a Novel Strategy of Network Pharmacology Screening.", "Nguyen, H. et al. (2023). Neurotherapeutic Effects of Quercetin and Its Metabolite Compounds on Cognitive Impairment and Parkinson's Disease: An In Silico Study.", "Yan, J. et al. (2023). Associations between variants in levodopa metabolic pathway genes and levodopa-induced dyskinesia in Parkinson's disease.", "Gao, Z. et al. (2023). Repurposing ketamine to treat cocaine use disorder: integration of artificial intelligence-based prediction, expert evaluation, clinical corroboration and mechanism of action analyses.", "Kalla, P. et al. (2023). Contrasting ABCB1 pharmacogenetics and psychotropic responses in child and adolescent psychiatry: a case comparison.", "Tang, H. et al. (2023). DRD2 expression based on (18)F-fallypride PET/MR predicts the dopamine agonist resistance of prolactinomas: a pilot study.", "Nguyen, H. et al. (2023). Risperidone ameliorated 1,2-Diacetylbenzene-induced cognitive impairments in mice via activating prolactin signaling pathways.", "Ghanbarzehi, A. et al. (2023). Disclosing common biological signatures and predicting new therapeutic targets in schizophrenia and obsessive-compulsive disorder by integrated bioinformatics analysis.", "Liu, J. et al. (2023). Pharmacogenomics-a New Frontier for Individualized Treatment of Parkinson's Disease.", "Cheng, Z. et al. (2023). Rasd2 Mediates Acute Fasting-Induced Antidepressant-Like Effects via Dopamine D2 Receptor Activation in Ovariectomized Mice.", "Wang, X. et al. (2023). Network pharmacology and LC-MS approachs to explore the active compounds and mechanisms of Yuanjiang decoction for treating bradyarrhythmia.", "Stelmach, A. et al. (2023). Antipsychotic drug-aripiprazole against schizophrenia, its therapeutic and metabolic effects associated with gene polymorphisms.", "Liu, X. et al. (2023). Dopamine D2 receptor agonist Bromocriptine ameliorates Abeta(1-42)-induced memory deficits and neuroinflammation in mice.", "Kibitov, A. et al. (2023). The ANKK1/DRD2 gene TaqIA polymorphism (rs1800497) is associated with the severity of extrapyramidal side effects of haloperidol treatment in CYP2D6 extensive metabolizers with schizophrenia spectrum disorders.", "Spitta, G. et al. (2022). Association between DRD2/ANKK1 TaqIA Allele Status and Striatal Dopamine D2/3 Receptor Availability in Alcohol Use Disorder.", "Blum, K. et al. (2022). Hypothesizing That Pediatric Autoimmune Neuropsychiatric Associated Streptococcal (PANDAS) Causes Rapid Onset of Reward Deficiency Syndrome (RDS) Behaviors and May Require Induction of \"Dopamine Homeostasis\".", "Meimei, C. et al. (2022). Discovery of Taxus chinensis fruit wine as potentially functional food against Alzheimer's disease by UHPLC-QE-MS/MS, network pharmacology and molecular docking.", "Mao, Y. et al. (2022). The Food and Drug Administration-approved antipsychotic drug trifluoperazine, a calmodulin antagonist, inhibits viral replication through PERK-eIF2alpha axis.", "Yen, E. et al. (2023). Sex-specific inflammatory and white matter effects of prenatal opioid exposure: a pilot study.", "Yang, Y. et al. (2022). Xiaoyao San ameliorates high-fat diet-induced anxiety and depression via regulating gut microbiota in mice.", "Liu, Y. et al. (2022). beta-Arrestin2-biased Drd2 agonist UNC9995 alleviates astrocyte inflammatory injury via interaction between beta-arrestin2 and STAT3 in mouse model of depression.", "Hajj, A. et al. (2022). Clinical and genetic factors associated with self-reported cognitive deficits in women with breast cancer: the \"CAGE-Cog\" study.", "Clauss, N. et al. (2022). The Modification of Offspring Stress-Related Behavior and the Expression of Drd1, Drd2, and Nr3c1 by a Western-Pattern Diet in Mus Musculus.", "White, O. et al. (2022). Prenatal Effects of Nicotine on Obesity Risks: A Narrative Review.", "Xin, J. et al. (2022). To explore the potential molecular mechanism of complex rose-bergamot essential oil on anti-anxiety with facial spots based on network pharmacology.", "Paderina, D. et al. (2022). The Gender-Specific Association of DRD2 Polymorphism with Metabolic Syndrome in Patients with Schizophrenia.", "Li, X. et al. (2022). Effects of Long-Term Administration of Q808 on Hippocampal Transcriptome in Healthy Rats.", "Vicchi, F. et al. (2022). Severe Hyperprolactinemia Promotes Brown Adipose Tissue Whitening and Aggravates High Fat Diet Induced Metabolic Imbalance.", "Carvalho, C. et al. (2022). Cannabis induced psychosis: A systematic review on the role of genetic polymorphisms.", "Biswas, M. et al. (2022). Pharmacogenomics in clinical practice to prevent risperidone-induced hyperprolactinemia in autism spectrum disorder.", "Tung, M. et al. (2022). Targeting DRD2 by the antipsychotic drug, penfluridol, retards growth of renal cell carcinoma via inducing stemness inhibition and autophagy-mediated apoptosis.", "Smiarowska, M. et al. (2022). Influence of COMT (rs4680) and DRD2 (rs1076560, rs1800497) Gene Polymorphisms on Safety and Efficacy of Methylphenidate Treatment in Children with Fetal Alcohol Spectrum Disorders.", "Zazueta, A. et al. (2022). Polymorphisms in Schizophrenia-Related Genes Are Potential Predictors of Antipsychotic Treatment Resistance and Refractoriness.", "Pelzer, E. et al. (2022). Clustering of Parkinson subtypes reveals strong influence of DRD2 polymorphism and gender.", "Peng, H. et al. (2022). Intestinal Dopamine Receptor D2 is Required for Neuroprotection Against 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Dopaminergic Neurodegeneration.", "Radojevic, B. et al. (2022). The correlation between genetic factors and freezing of gait in patients with Parkinson's disease.", "Fan, Y. et al. (2022). Anti-Tumor and Anti-Invasive Effects of ONC201 on Ovarian Cancer Cells and a Transgenic Mouse Model of Serous Ovarian Cancer.", "Wang, J. et al. (2022). The D2R-DISC1 protein complex and associated proteins are altered in schizophrenia and normalized with antipsychotic treatment.", "Tucker, K. et al. (2022). ONC206 has anti-tumorigenic effects in human ovarian cancer cells and in a transgenic mouse model of high-grade serous ovarian cancer.", "Parande, F. et al. (2022). Effect of Dietary Grapes on Female C57BL6/J Mice Consuming a High-Fat Diet: Behavioral and Genetic Changes.", "Soraya, G. et al. (2022). Polymorphisms of the dopamine metabolic and signaling pathways are associated with susceptibility to motor levodopa-induced complications (MLIC) in Parkinson's disease: a systematic review and meta-analysis.", "Yan, Q. et al. (2022). HERV-W Envelope Triggers Abnormal Dopaminergic Neuron Process through DRD2/PP2A/AKT1/GSK3 for Schizophrenia Risk.", "Dehelean, L. et al. (2021). Impairment of the cardiac ejection fraction by blocking dopamine D2 receptors induced by long-acting injectable antipsychotic treatment.", "Hajj, A. et al. (2022). Fatigue in breast cancer patients on chemotherapy: a cross-sectional study exploring clinical, biological, and genetic factors.", "Staley, A. et al. (2021). Highly potent dopamine receptor D2 antagonist ONC206 demonstrates anti-tumorigenic activity in endometrial cancer.", "Korlatowicz, A. et al. (2021). Identification of Molecular Markers of Clozapine Action in Ketamine-Induced Cognitive Impairment: A GPCR Signaling PathwayFinder Study.", "Bharti, N. et al. (2021). Genetic diversity of 'Very Important Pharmacogenes' in two South-Asian populations.", "Wang, S. et al. (2021). The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas.", "Frederick, N. et al. (2021). Pharmacological perturbation reveals deficits in D2 receptor responses in Thap1 null mice.", "Yang, Y. et al. (2022). Salvianolic acid A relieves cognitive disorder after chronic cerebral ischemia: Involvement of Drd2/Cryab/NF-kappaB pathway.", "Wei, S. et al. (2021). Pramipexole regulates depression-like behavior via dopamine D3 receptor in a mouse model of Parkinson's disease.", "Mosquera, M. et al. (2022). Extracellular Matrix in Synthetic Hydrogel-Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors.", "Ahmad, M. et al. (2021). Naringenin alleviates paraquat-induced dopaminergic neuronal loss in SH-SY5Y cells and a rat model of Parkinson's disease.", "Qing, J. et al. (2022). Dopamine receptor D2 antagonism normalizes profibrotic macrophage-endothelial crosstalk in non-alcoholic steatohepatitis.", "Morozova, M. et al. (2022). Treatment Response and GWAS Risk Allele rs2514218 (C) of the Dopamine D2 Receptor Gene in Inpatients with Schizophrenia.", "Takahashi, Y. et al. (2021). Aberrant neurogenesis and late onset suppression of synaptic plasticity as well as sustained neuroinflammation in the hippocampal dentate gyrus after developmental exposure to ethanol in rats.", "Zubiaur, P. et al. (2021). The pharmacogenetics of treatment with olanzapine.", "Zhang, J. et al. (2021). Methylation quantitative trait locus rs5326 is associated with susceptibility and effective dosage of methadone maintenance treatment for heroin use disorder.", "Free, R. et al. (2021). Pharmacological Characterization of the Imipridone Anticancer Drug ONC201 Reveals a Negative Allosteric Mechanism of Action at the D(2) Dopamine Receptor.", "Hajj, A. et al. (2021). Clinical and genetic factors associated with anxiety and depression in breast cancer patients: a cross-sectional study.", "Whiting, R. et al. (2021). Preclinical Evaluation of the Effects of Trazpiroben (TAK-906), a Novel, Potent Dopamine D(2)/D(3) Receptor Antagonist for the Management of Gastroparesis.", "Deshetty, U. et al. (2021). Menthol, a bioactive constituent of Mentha, attenuates motion sickness in mice model: Involvement of dopaminergic system.", "Russo, E. et al. (2022). Cannabinoid Hyperemesis Syndrome Survey and Genomic Investigation.", "Cruz, A. et al. (2021). Dopamine Receptors in Cancer: Are They Valid Therapeutic Targets?", "Ivanov, H. et al. (2021). Exploring pharmacogenetic variation in a Bulgarian psychiatric cohort.", "Andreoli, L. et al. (2021). Distinct patterns of dyskinetic and dystonic features following D1 or D2 receptor stimulation in a mouse model of parkinsonism.", "Radojevic, B. et al. (2021). Clinical and Genetic Analysis of Psychosis in Parkinson's Disease.", "Islam, F. et al. (2021). Pharmacogenetics-Guided Advances in Antipsychotic Treatment.", "Zarrin, P. et al. (2021). Liposomal Form of L-Dopa and SH-Sy5y Cell-Derived Exosomes Modulate the Tyrosine Hydroxylase/Dopamine Receptor D2 Signaling Pathway in Parkinson's Rat Models.", "Cacabelos, R. et al. (2021). Atremorine in Parkinson's disease: From dopaminergic neuroprotection to pharmacogenomics.", "She, X. et al. (2021). A high-throughput screen identifies inhibitors of lung cancer stem cells.", "Li, S. et al. (2021). Study on Hepatotoxicity of Rhubarb Based on Metabolomics and Network Pharmacology.", "Tavares, G. et al. (2021). Dopamine D2 receptor agonist, bromocriptine, remodels adipose tissue dopaminergic signalling and upregulates catabolic pathways, improving metabolic profile in type 2 diabetes.", "Dao, C. et al. (2021). The impact of removing former drinkers from genome-wide association studies of AUDIT-C.", "Hajj, A. et al. (2021). Negative symptoms in schizophrenia: correlation with clinical and genetic factors.", "Lu, K. et al. (2021). Dopamine Prevents Ultraviolet B-induced Development and Progression of Premalignant Cutaneous Lesions through its D(2) Receptors.", "Franklin, J. et al. (2021). Cannabinoid 2 receptors regulate dopamine 2 receptor expression by a beta-arrestin 2 and GRK5-dependent mechanism in neuronal cells.", "Zahari, Z. et al. (2020). Influence of DRD2 Polymorphisms on the Clinical Outcomes of Opioiddependent Patients on Methadone Maintenance Therapy.", "Tang, H. et al. (2021). Case Report: Temozolomide Treatment of Refractory Prolactinoma Resistant to Dopamine Agonists.", "Rossow, K. et al. (2021). Evidence for Pharmacogenomic Effects on Risperidone Outcomes in Pediatrics.", "Santos, L. et al. (2021). Perinatal exposure to a high-fat diet alters proopiomelanocortin, neuropeptide Y and dopaminergic receptors gene expression and the food preference in offspring adult rats.", "Hajj, A. et al. (2021). Clinical and Genetic Factors Associated With the Breast Cancer-Related Sleep Disorders: The \"CAGE-Sleep\" Study-A Cross-Sectional Study.", "Pierce, S. et al. (2021). Targeting dopamine receptor D2 as a novel therapeutic strategy in endometrial cancer.", "Olsen, D. et al. (2021). Altered dopaminergic firing pattern and novelty response underlie ADHD-like behavior of SorCS2-deficient mice.", "Rebelo, D. et al. (2021). A link between synaptic plasticity and reorganization of brain activity in Parkinson's disease.", "Kimura, M. et al. (2021). Effects of repeated electroconvulsive shocks on dopamine supersensitivity psychosis model rats.", "Zubiaur, P. et al. (2021). Impact of polymorphisms in transporter and metabolizing enzyme genes on olanzapine pharmacokinetics and safety in healthy volunteers.", "Arranz, M. et al. (2021). Pharmacogenetics of antipsychotics: Clinical utility and implementation.", "Song, Y. et al. (2020). Thioridazine hydrochloride: an antipsychotic agent that inhibits tumor growth and lung metastasis in triple-negative breast cancer via inducing G0/G1 arrest and apoptosis.", "Mullally, J. et al. (2021). Weight-loss response to naltrexone/bupropion is modulated by the Taq1A genetic variant near DRD2 (rs1800497): A pilot study.", "Yoshida, K. et al. (2021). Pharmacogenomic Studies in Intellectual Disabilities and Autism Spectrum Disorder: A Systematic Review.", "Zhang, Y. et al. (2020). ONC206, an Imipridone Derivative, Induces Cell Death Through Activation of the Integrated Stress Response in Serous Endometrial Cancer In Vitro.", "Xu, C. et al. (2021). Effects of Yuanhu- Zhitong tablets on alcohol-induced conditioned place preference in mice.", "Santos, E. et al. (2020). Pharmacogenetic profile and the development of the dyskinesia induced by levodopa-therapy in Parkinson's disease patients: a population-based cohort study.", "Prabhu, V. et al. (2020). ONC201 and imipridones: Anti-cancer compounds with clinical efficacy.", "Ortiz, D. et al. (2021). The dopaminergic alterations induced by 4-F-PCP and 4-Keto-PCP may enhance their drug-induced rewarding and reinforcing effects: Implications for abuse.", "Li, H. et al. (2021). Pepper component 7-ethoxy-4-methylcoumarin, a novel dopamine D2 receptor agonist, ameliorates experimental Parkinson's disease in mice and Caenorhabditis elegans.", "Yan, P. et al. (2020). Association of the genetic polymorphisms of metabolizing enzymes, transporters, target receptors and their interactions with treatment response to olanzapine in chinese han schizophrenia patients.", "Koller, D. et al. (2021). Safety and cardiovascular effects of multiple-dose administration of aripiprazole and olanzapine in a randomised clinical trial.", "Nishibe, H. et al. (2021). Striatal Dopamine D2 Receptor Occupancy Induced by Daily Application of Blonanserin Transdermal Patches: Phase II Study in Japanese Patients With Schizophrenia.", "Punchaichira, T. et al. (2020). The effect of rs1076560 (DRD2) and rs4680 (COMT) on tardive dyskinesia and cognition in schizophrenia subjects.", "Cherrier, K. et al. (2020). Cocaine-mediated circadian reprogramming in the striatum through dopamine D2R and PPARgamma activation.", "Kanahara, N. et al. (2020). The effectiveness of very slow switching to aripiprazole in schizophrenia patients with dopamine supersensitivity psychosis: a case series from an open study.", "He, Y. et al. (2021). Epidermal growth factor receptor as a molecular determinant of glioblastoma response to dopamine receptor D2 inhibitors.", "Ivashchenko, D. et al. (2020). Pharmacogenetics of antipsychotics in adolescents with acute psychotic episode during first 14 days after admission: effectiveness and safety evaluation.", "Kravtsov, V. et al. (2020). [Pharmacogenetic aspects of the dopaminergic system in clozapine pharmacodynamics].", "Oh, H. et al. (2021). Role of rs6265 BDNF polymorphisms and post-stroke dysphagia recovery-A prospective cohort study.", "Perrone, M. et al. (2021). Diffuse Intrinsic Pontine Glioma (DIPG): Breakthrough and Clinical Perspective.", "Nair, A. et al. (2020). An update on the efficacy and safety of iloperidone as a schizophrenia therapy.", "Redensek, S. et al. (2020). Clinical and Clinical-Pharmacogenetic Models for Prediction of the Most Common Psychiatric Complications Due to Dopaminergic Treatment in Parkinson's Disease.", "Feistauer, V. et al. (2020). Restriction and hyperlipidic diets during pregnancy, lactation and adult life modified the expression of dopaminergic system related genes both in female mice and their adult offspring.", "Liu, Y. et al. (2020). The KBTBD6/7-DRD2 axis regulates pituitary adenoma sensitivity to dopamine agonist treatment.", "Molitch, M. et al. (2020). Dopamine agonists and antipsychotics.", "Arakawa, R. et al. (2020). PET technology for drug development in psychiatry.", "Forrester, S. et al. (2020). Depression Onset in Long-term Adolescent Cannabinoid Use: A Neurobiological Review.", "Amir, Q. et al. (2020). Synonymous polymorphism rs201256011 in dopamine receptor type 2 gene is associated with schizophrenia and PANSS score in Pakistani population: A first report.", "Fedorenko, O. et al. (2020). Association of ANKK1 polymorphism with antipsychotic-induced hyperprolactinemia.", "Zivkovic, M. et al. (2020). Remission Is not Associated with DRD2 rs1800497 and DAT1 rs28363170 Genetic Variants in Male Schizophrenic Patients after 6-months Monotherapy with Olanzapine.", "Jerome, R. et al. (2020). Exploring Biologic Predictors Response Disparities to Atypical Antipsychotics among Blacks: A Quasi-Systematic Review.", "Koller, D. et al. (2020). The effects of aripiprazole and olanzapine on pupillary light reflex and its relationship with pharmacogenetics in a randomized multiple-dose trial.", "Keks, N. et al. (2020). Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia.", "Zakharyan, R. et al. (2020). Association of Genetic Variants of Dopamine and Serotonin In Schizophrenia.", "Gasso, P. et al. (2020). Association study of candidate genes with obesity and metabolic traits in antipsychotic-treated patients with first-episode psychosis over a 2-year period.", "Luo, D. et al. (2020). Lithium for schizophrenia: supporting evidence from a 12-year, nationwide health insurance database and from Akt1-deficient mouse and cellular models.", "Lopez, O. et al. (2019). Interactions between DRD2/ANKK1 TaqIA Polymorphism and Dietary Factors Influence Plasma Triglyceride Concentrations in Diabetic Patients from Western Mexico: A Cross-sectional Study.", "Custodio, R. et al. (2020). 25B-NBOMe, a novel N-2-methoxybenzyl-phenethylamine (NBOMe) derivative, may induce rewarding and reinforcing effects via a dopaminergic mechanism: Evidence of abuse potential.", "Romany, I. et al. (2020). Biological activity of weekly ONC201 in adult recurrent glioblastoma patients.", "Veselinovic, T. et al. (2019). Dopamine D2 Receptor Occupancy Estimated From Plasma Concentrations of Four Different Antipsychotics and the Subjective Experience of Physical and Mental Well-Being in Schizophrenia: Results From the Randomized NeSSy Trial.", "Rossetti, M. et al. (2020). Epigenetic Dysregulation of Dopaminergic System by Maternal Cafeteria Diet During Early Postnatal Development.", "Zhao, J. et al. (2019). Different roles of Rac1 in the acquisition and extinction of methamphetamine-associated contextual memory in the nucleus accumbens.", "Hajj, A. et al. (2019). Clinical and Genetic Factors Associated with Resistance to Treatment in Patients with Schizophrenia: A Case-Control Study.", "Koller, D. et al. (2020). Effects of aripiprazole on circadian prolactin secretion related to pharmacogenetics in healthy volunteers.", "Puangpetch, A. et al. (2019). Association between polymorphisms of LEP, LEPR, DRD2, HTR2A and HTR2C genes and risperidone- or clozapine-induced hyperglycemia.", "Yen, E. et al. (2019). Sex-Dependent Gene Expression in Infants with Neonatal Opioid Withdrawal Syndrome.", "Chi, A. et al. (2019). Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.", "Kubi, P. et al. (2019). Probing Binding Landscapes and Molecular Recognition Mechanisms of Atypical Antipsychotic Drugs towards the Selective Targeting of D(2) Dopamine Receptor.", "Mallet, J. et al. (2019). Major Depressive Disorder (MDD) and Schizophrenia- Addressing Unmet Needs With Partial Agonists at the D2 Receptor: A Review.", "Wang, D. et al. (2020). Pharmacogenomics analysis in Chinese pediatric liver transplantation patients with renal toxicity induced by tacrolimus.", "Esdonk, M. et al. (2019). The Pharmacodynamic Effects of a Dopamine-Somatostatin Chimera Agonist on the Cardiovascular System.", "Akbarian, F. et al. (2019). Novel Insight into Differential Gene Expression and Clinical Significance of Dopamine Receptors, COMT, and IL6 in BPH and Prostate Cancer.", "Wang, X. et al. (2019). The Prospective Value of Dopamine Receptors on Bio-Behavior of Tumor.", "Stein, M. et al. (2019). Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration.", "Ma, L. et al. (2019). Association of dopamine D2 receptor gene polymorphisms with prolactin levels related to risperidone treatment: A systematic review and meta-analysis.", "Thangaraj, A. et al. (2020). Mitigation of cocaine-mediated mitochondrial damage, defective mitophagy and microglial activation by superoxide dismutase mimetics.", "Osmanova, D. et al. (2019). A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia.", "Gutierrez, A. et al. (2019). Effects of intrastriatal dopamine D1 or D2 antagonists on methamphetamine-induced egocentric and allocentric learning and memory deficits in Sprague-Dawley rats.", "Wang, Y. et al. (2019). Prenatal Tobacco Exposure Modulated the Association of Genetic variants with Diagnosed ADHD and its symptom domain in children: A Community Based Case-Control Study.", "Asaoka, N. et al. (2019). An Adenosine A(2A) Receptor Antagonist Improves Multiple Symptoms of Repeated Quinpirole-Induced Psychosis.", "Santos, E. et al. (2019). Pharmacogenetic Profile and the Occurrence of Visual Hallucinations in Patients With Sporadic Parkinson's Disease.", "During, S. et al. (2019). Sexual dysfunction and hyperprolactinemia in schizophrenia before and after six weeks of D(2/3) receptor blockade - An exploratory study.", "Li, J. et al. (2019). Candidate gene analyses for acute pain and morphine analgesia after pediatric day surgery: African American versus European Caucasian ancestry and dose prediction limits.", "Zorick, T. et al. (2019). Effects of Citalopram on Cue-Induced Alcohol Craving and Thalamic D2/3 Dopamine Receptor Availability.", "Coelho, M. et al. (2019). Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles.", "Naito, T. et al. (2019). Optimization of Individual Pharmacotherapy Based on Multiple Evaluations of Patient Data.", "Levchenko, A. et al. (2019). No evidence so far of a major role of AKT1 and GSK3B in the pathogenesis of antipsychotic-induced tardive dyskinesia.", "Prabhu, V. et al. (2019). Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism.", "Hakim, J. et al. (2019). Prolonged ad libitum access to low-concentration sucrose changes the neurochemistry of the nucleus accumbens in male Sprague-Dawley rats.", "Carvalho, L. et al. (2019). High-fat diet withdrawal modifies alcohol preference and transcription of dopaminergic and GABAergic receptors.", "Wu, D. et al. (2018). Inhibition of microRNA-200a Upregulates the Expression of Striatal Dopamine Receptor D2 to Repress Apoptosis of Striatum via the cAMP/PKA Signaling Pathway in Rats with Parkinson's Disease.", "Escamilla, R. et al. (2018). Association study between COMT, DRD2, and DRD3 gene variants and antipsychotic treatment response in Mexican patients with schizophrenia.", "Oishi, K. et al. (2018). Vulnerable combinations of functional dopaminergic polymorphisms to late-onset treatment resistant schizophrenia.", "Santos, E. et al. (2019). The influence of SLC6A3 and DRD2 polymorphisms on levodopa-therapy in patients with sporadic Parkinson's disease.", "Alladi, C. et al. (2019). Dopamine (DRD2) and Serotonin (HTR2A, 2C) Receptor Gene Polymorphisms do not influence early response to Risperidone in South Indian Patients with Schizophrenia.", "McCarthy, D. et al. (2018). Nicotine exposure of male mice produces behavioral impairment in multiple generations of descendants.", "Chu, C. et al. (2019). Association Between Polymorphisms in Dopamine-Related Genes and Orthopedic Pain Expression in a Chinese Elderly Population.", "Koller, D. et al. (2018). Effects of aripiprazole on pupillometric parameters related to pharmacokinetics and pharmacogenetics after single oral administration to healthy subjects.", "Cui, Y. et al. (2018). Dopamine receptor D2 gene polymorphism, urine fluoride, and intelligence impairment of children in China: A school-based cross-sectional study.", "Ozzoude, M. et al. (2019). The effects of illness severity, cognition, and estimated antipsychotic dopamine receptor occupancy on insight into the illness in schizophrenia: An analysis of clinical antipsychotic trials of intervention effectiveness (CATIE) data.", "Lu, J. et al. (2018). Association study of Disrupted-In-Schizophrenia-1 gene variants and tardive dyskinesia.", "Ma, L. et al. (2019). Association between dopamine receptor gene polymorphisms and effects of risperidone treatment: A systematic review and meta-analysis.", "Aslostovar, L. et al. (2018). A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia.", "Wolfe, D. et al. (2018). Drug Refraining and Seeking Potentiate Synapses on Distinct Populations of Accumbens Medium Spiny Neurons.", "Xu, Z. et al. (2018). SP8 and SP9 coordinately promote D2-type medium spiny neuron production by activating Six3 expression.", "Kurylev, A. et al. (2018). The combined effect of CYP2D6 and DRD2 Taq1A polymorphisms on the antipsychotics daily doses and hospital stay duration in schizophrenia inpatients (observational naturalistic study).", "Salloum, N. et al. (2018). From genes to treatments: a systematic review of the pharmacogenetics in smoking cessation.", "Tozzi, A. et al. (2018). Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease.", "Yang, Y. et al. (2018). Repositioning Dopamine D2 Receptor Agonist Bromocriptine to Enhance Docetaxel Chemotherapy and Treat Bone Metastatic Prostate Cancer.", "McDonell, K. et al. (2018). Taq1A polymorphism and medication effects on inhibitory action control in Parkinson disease.", "Gasso, P. et al. (2018). Impact of NTRK2, DRD2 and ACE polymorphisms on prolactin levels in antipsychotic-treated patients with first-episode psychosis.", "Ankney, B. et al. (2018). Persistent effects of obesity: a neuroplasticity hypothesis.", "Krupkova, M. et al. (2018). Single-Gene Congenic Strain Reveals the Effect of Zbtb16 on Dexamethasone-Induced Insulin Resistance.", "Armando, I. et al. (2018). Antihypertensive effect of etamicastat in dopamine D2 receptor-deficient mice.", "Zhang, J. et al. (2018). Recent Progress in Pharmacogenomics of Antipsychotic Drug Response.", "Zai, C. et al. (2018). Genetics of tardive dyskinesia: Promising leads and ways forward.", "Duan, L. et al. (2018). [Association between DRD2 gene polymorphisms and the dosage used on methadone maintenance treatment program].", "Yanovich, C. et al. (2018). Social rank-associated stress vulnerability predisposes individuals to cocaine attraction.", "Sukasem, C. et al. (2018). Pharmacogenetics of Risperidone-Induced Insulin Resistance in Children and Adolescents with Autism Spectrum Disorder.", "Schacht, J. et al. (2018). Dopaminergic Genetic Variation Influences Aripiprazole Effects on Alcohol Self-Administration and the Neural Response to Alcohol Cues in a Randomized Trial.", "Fan, X. et al. (2018). Dopamine Receptor Agonist Treatment of Idiopathic Dystonia: A Reappraisal in Humans and Mice.", "Politi, C. et al. (2018). Genetics and Treatment Response in Parkinson's Disease: An Update on Pharmacogenetic Studies.", "Miller, N. et al. (2018). Dopaminergic polymorphisms associated with medication responsiveness of gait in Parkinson's disease.", "Kusters, C. et al. (2018). Dopamine receptors and BDNF-haplotypes predict dyskinesia in Parkinson's disease.", "Burstein, O. et al. (2017). Escitalopram and NHT normalized stress-induced anhedonia and molecular neuroadaptations in a mouse model of depression.", "Dorey, E. et al. (2018). The impact of periconceptional alcohol exposure on fat preference and gene expression in the mesolimbic reward pathway in adult rat offspring.", "Tarland, E. et al. (2018). Effects of 2-bromoterguride, a dopamine D(2) receptor partial agonist, on cognitive dysfunction and social aversion in rats.", "Sykes, D. et al. (2017). Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D(2) receptors.", "Guin, D. et al. (2017). A systematic review and integrative approach to decode the common molecular link between levodopa response and Parkinson's disease.", "Nakata, Y. et al. (2017). Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice.", "Politis, M. et al. (2017). Chronic exposure to dopamine agonists affects the integrity of striatal D(2) receptors in Parkinson's patients.", "Sanchez, C. et al. (2017). Pharmacogenetics of methylphenidate in childhood attention-deficit/hyperactivity disorder: long-term effects.", "Pecina, M. et al. (2017). Striatal dopamine D2/3 receptor-mediated neurotransmission in major depression: Implications for anhedonia, anxiety and treatment response.", "Gao, L. et al. (2018). A computational network analysis based on targets of antipsychotic agents.", "Zastrozhin, M. et al. (2017). Pharmacodynamic genetic polymorphisms affect adverse drug reactions of haloperidol in patients with alcohol-use disorder.", "Shi, Y. et al. (2017). Combined study of genetic and epigenetic biomarker risperidone treatment efficacy in Chinese Han schizophrenia patients.", "Kaur, G. et al. (2017). Identification of genetic correlates of response to Risperidone: Findings of a multicentric schizophrenia study from India.", "Eum, S. et al. (2017). Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report.", "Moeller, S. et al. (2018). Low Striatal Dopamine D2-type Receptor Availability is Linked to Simulated Drug Choice in Methamphetamine Users.", "Oki, M. et al. (2017). Zonisamide ameliorates levodopa-induced dyskinesia and reduces expression of striatal genes in Parkinson model rats.", "Flynn, M. et al. (2017). Mechanism of Off-Target Interactions and Toxicity of Tamoxifen and Its Metabolites.", "Wit, I. et al. (2017). Dopamine D2-receptor affinity of antipsychotics in relation to subjective well-being in patients with a psychotic disorder.", "Nuntamool, N. et al. (2017). Pharmacogenomics and Efficacy of Risperidone Long-Term Treatment in Thai Autistic Children and Adolescents.", "Alladi, C. et al. (2017). Risperidone-Induced Adverse Drug Reactions and Role of DRD2 (-141 C Ins/Del) and 5HTR2C (-759 C>T) Genetic Polymorphisms in Patients with Schizophrenia.", "Stein, M. et al. (2017). First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors.", "Nielson, J. et al. (2017). Uncovering precision phenotype-biomarker associations in traumatic brain injury using topological data analysis.", "Schrantee, A. et al. (2017). Repeated dexamphetamine treatment alters the dopaminergic system and increases the phMRI response to methylphenidate.", "Markovic, M. et al. (2017). Brexpiprazole.", "Pergola, G. et al. (2017). DRD2 co-expression network and a related polygenic index predict imaging, behavioral and clinical phenotypes linked to schizophrenia.", "Iwata, Y. et al. (2016). Threshold of Dopamine D2/3 Receptor Occupancy for Hyperprolactinemia in Older Patients With Schizophrenia.", "Spiros, A. et al. (2017). Semi-mechanistic computer simulation of psychotic symptoms in schizophrenia with a model of a humanized cortico-striatal-thalamocortical loop.", "Bueno, C. et al. (2017). Cabergoline and prolactinomas: lack of association between DRD2 polymorphisms and response to treatment.", "Xu, S. et al. (2017). Association of the DRD2 CA(n)-STR and DRD3 Ser9Gly polymorphisms with Parkinson's disease and response to dopamine agonists.", "Mukoyama, N. et al. (2016). An Analysis of Behavioral and Genetic Risk Factors for Chemotherapy-Induced Nausea and Vomiting in Japanese Subjects.", "Beyer, J. et al. (2016). Adjunctive brexpiprazole for the treatment of major depressive disorder.", "Rieck, M. et al. (2018). Association between DRD2 and DRD3 gene polymorphisms and gastrointestinal symptoms induced by levodopa therapy in Parkinson's disease.", "Kohno, M. et al. (2016). Midbrain functional connectivity and ventral striatal dopamine D2-type receptors: link to impulsivity in methamphetamine users.", "Seeman, P. et al. (2016). Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose.", "Nohesara, S. et al. (2016). Methamphetamine-induced psychosis is associated with DNA hypomethylation and increased expression of AKT1 and key dopaminergic genes.", "Qiu, J. et al. (2016). Sinomenine activates astrocytic dopamine D2 receptors and alleviates neuroinflammatory injury via the CRYAB/STAT3 pathway after ischemic stroke in mice.", "Pivonello, C. et al. (2017). Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study.", "Papenberg, G. et al. (2017). Dopamine Receptor Genes Modulate Associative Memory in Old Age.", "Allen, J. et al. (2016). Discovery and clinical introduction of first-in-class imipridone ONC201.", "Huang, T. et al. (2016). A new method for identifying causal genes of schizophrenia and anti-tuberculosis drug-induced hepatotoxicity.", "Girgis, R. et al. (2016). Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO.", "Colzato, L. et al. (2016). Effects of l-Tyrosine on working memory and inhibitory control are determined by DRD2 genotypes: A randomized controlled trial.", "Terzic, T. et al. (2016). Genetic polymorphisms in dopaminergic system and treatment-resistant schizophrenia.", "Mas, S. et al. (2016). Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes.", "Schacht, J. et al. (2016). COMT val158met moderation of dopaminergic drug effects on cognitive function: a critical review.", "Saghazadeh, A. et al. (2016). Genetic polymorphisms and the adequacy of brain stimulation: state of the art.", "Zhang, J. et al. (2016). Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis.", "Masellis, M. et al. (2016). Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study.", "Peculis, R. et al. (2016). Polymorphisms in MEN1 and DRD2 genes are associated with the occurrence and characteristics of pituitary adenomas.", "Bramness, J. et al. (2016). Psychosis induced by amphetamines.", "Blum, K. et al. (2017). Common Neurogenetic Diagnosis and Meso-Limbic Manipulation of Hypodopaminergic Function in Reward Deficiency Syndrome (RDS): Changing the Recovery Landscape.", "Charan, A. et al. (2016). Relation between serum prolactin levels and antipsychotic response to risperidone in patients with schizophrenia.", "Kraemmer, J. et al. (2016). Clinical-genetic model predicts incident impulse control disorders in Parkinson's disease.", "Carlin, J. et al. (2016). Removal of high-fat diet after chronic exposure drives binge behavior and dopaminergic dysregulation in female mice.", "Philpott, A. et al. (2016). A GABBR2 gene variant modifies pathophysiology in Huntington's disease.", "Hirth, N. et al. (2016). Convergent evidence from alcohol-dependent humans and rats for a hyperdopaminergic state in protracted abstinence.", "Georgiou, P. et al. (2016). Methamphetamine abstinence induces changes in mu-opioid receptor, oxytocin and CRF systems: Association with an anxiogenic phenotype.", "Junior, A. et al. (2016). Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents.", "Sukasem, C. et al. (2016). Impact of Pharmacogenetic Markers of CYP2D6 and DRD2 on Prolactin Response in Risperidone-Treated Thai Children and Adolescents With Autism Spectrum Disorders.", "Emig, H. et al. (2016). Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology.", "Pagerols, M. et al. (2017). Pharmacogenetics of methylphenidate response and tolerability in attention-deficit/hyperactivity disorder.", "Gressier, F. et al. (2016). Pharmacogenetics of clozapine response and induced weight gain: A comprehensive review and meta-analysis.", "A, C. et al. (2016). [A pharmacogenetic analysis of dopaminergic and opioidergic genes in opioid addicts treated with the combination of naltrexone and guanfacine].", "Junior, A. et al. (2015). Hyperprolactinemia in Children and Adolescents with Use of Risperidone: Clinical and Molecular Genetics Aspects.", "Huang, E. et al. (2016). Preliminary evidence for association of genome-wide significant DRD2 schizophrenia risk variant with clozapine response.", "Ballard, M. et al. (2015). Striatal Dopamine D2/D3 Receptor Availability Is Associated with Executive Function in Healthy Controls but Not Methamphetamine Users.", "Okita, K. et al. (2016). Relationship of Alexithymia Ratings to Dopamine D2-type Receptors in Anterior Cingulate and Insula of Healthy Control Subjects but Not Methamphetamine-Dependent Individuals.", "Ebdrup, B. et al. (2016). Frontal fasciculi and psychotic symptoms in antipsychotic-naive patients with schizophrenia before and after 6 weeks of selective dopamine D2/3 receptor blockade.", "Adams, W. et al. (2015). Long-term, calorie-restricted intake of a high-fat diet in rats reduces impulse control and ventral striatal D2 receptor signalling - two markers of addiction vulnerability.", "Ilhan, M. et al. (2015). Does DRD2 polymorphism influence the clinical characteristics of prolactinoma?", "Tsuneki, H. et al. (2016). Nighttime Administration of Nicotine Improves Hepatic Glucose Metabolism via the Hypothalamic Orexin System in Mice.", "Choi, C. et al. (2015). High sucrose consumption during pregnancy induced ADHD-like behavioral phenotypes in mice offspring.", "Kleinjan, M. et al. (2015). Parental smoke exposure and the development of nicotine craving in adolescent novice smokers: the roles of DRD2, DRD4, and OPRM1 genotypes.", "Ciano, P. et al. (2016). Varenicline-Induced Elevation of Dopamine in Smokers: A Preliminary [(11)C]-(+)-PHNO PET Study.", "Bawor, M. et al. (2015). Contribution of BDNF and DRD2 genetic polymorphisms to continued opioid use in patients receiving methadone treatment for opioid use disorder: an observational study.", "Zhang, J. et al. (2015). Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis.", "Wang, D. et al. (2015). Studies on the regulatory effect of Peony-Glycyrrhiza Decoction on prolactin hyperactivity and underlying mechanism in hyperprolactinemia rat model.", "Frey, U. et al. (2016). Postoperative nausea and vomiting: The role of the dopamine D2 receptor TaqIA polymorphism.", "Volkow, N. et al. (2015). Recovery of dopamine transporters with methamphetamine detoxification is not linked to changes in dopamine release.", "Tomaz, P. et al. (2015). CYP2B6 rs2279343 polymorphism is associated with smoking cessation success in bupropion therapy.", "Patriquin, M. et al. (2015). Addiction pharmacogenetics: a systematic review of the genetic variation of the dopaminergic system.", "ka, N. et al. (2014). [USAGE OF PRONORAN(R) FOR TREATMENT OF ELDERLY PATIENTS WITH MILD COGNITIVE IMPAIRMENT].", "Foll, B. et al. (2016). Occupancy of Dopamine D3 and D2 Receptors by Buspirone: A [11C]-(+)-PHNO PET Study in Humans.", "Naumovska, Z. et al. (2015). Pharmacogenetics and antipsychotic treatment response.", "Ramoz, N. et al. (2015). [A genetic view of addiction].", "Choi, H. et al. (2015). Lack of association between DRD2 Taq1A gene polymorphism and smoking cessation therapy: a meta-analysis.", "Lencz, T. et al. (2015). Targeting the schizophrenia genome: a fast track strategy from GWAS to clinic.", "Colizzi, M. et al. (2015). Interaction Between Functional Genetic Variation of DRD2 and Cannabis Use on Risk of Psychosis.", "Cunha, F. et al. (2015). Both food restriction and high-fat diet during gestation induce low birth weight and altered physical activity in adult rat offspring: the \"Similarities in the Inequalities\" model.", "Kang, S. et al. (2015). DRD2 genotypic and haplotype variation is associated with improvements in negative symptoms after 6 weeks' amisulpride treatment.", "Bakker, P. et al. (2015). [The genetics of antipsychotic-related movement disorders].", "Yin, L. et al. (2015). TPH, SLC6A2, SLC6A3, DRD2 and DRD4 Polymorphisms and Neuroendocrine Factors Predict SSRIs Treatment Outcome in the Chinese Population with Major Depression.", "Blasi, G. et al. (2015). Variation in Dopamine D2 and Serotonin 5-HT2A Receptor Genes is Associated with Working Memory Processing and Response to Treatment with Antipsychotics.", "Mouly, S. et al. (2015). Methadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity.", "Levran, O. et al. (2014). Dopaminergic pathway polymorphisms and heroin addiction: further support for association of CSNK1E variants.", "Deng, X. et al. (2015). Association between DRD2/ANKK1 TaqIA polymorphism and common illicit drug dependence: evidence from a meta-analysis.", "Ortez, C. et al. (2015). Cerebrospinal fluid synaptic proteins as useful biomarkers in tyrosine hydroxylase deficiency.", "Wei, L. et al. (2015). Dopamine receptor DR2 expression in B cells is negatively correlated with disease activity in rheumatoid arthritis patients.", "Neto, L. et al. (2015). Dopamine receptor subtype 2 expression profile in nonfunctioning pituitary adenomas and in vivo response to cabergoline therapy.", "Huang, C. et al. (2015). Cocaine Withdrawal Impairs mGluR5-Dependent Long-Term Depression in Nucleus Accumbens Shell Neurons of Both Direct and Indirect Pathways.", "ianenko, V. et al. (2014). [Use of itopride in the symptoms of functional dyspepsia in Russia: results of a phase IV prospective open-label multicenter clinical trial].", "Sriram, K. et al. (2014). Neurotoxicity following acute inhalation of aerosols generated during resistance spot weld-bonding of carbon steel.", "Moore, T. et al. (2014). Pharmacogenomics in psychiatry: implications for practice.", "Bousman, C. et al. (2015). Effects of COMT, DRD2, BDNF, and APOE Genotypic Variation on Treatment Efficacy and Cognitive Side Effects of Electroconvulsive Therapy.", "Schuh, A. et al. (2014). Parkinson's disease pharmacogenomics: new findings and perspectives.", "Morrissette, D. et al. (2014). Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy.", "Cargnin, S. et al. (2014). Combined effect of common gene variants on response to drug withdrawal therapy in medication overuse headache.", "Bishop, J. et al. (2015). Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophrenia.", "Demin, A. et al. (2014). [Modern approaches to the primary prevention of the development of psychoactive substance dependence on the base of accounting of environmental and genetic risk factors].", "Somogyi, A. et al. (2014). Pharmacogenomics of methadone maintenance treatment.", "Tybura, P. et al. (2014). Pharmacogenetics of adverse events in schizophrenia treatment: comparison study of ziprasidone, olanzapine and perazine.", "Chun, S. et al. (2014). Specific disruption of thalamic inputs to the auditory cortex in schizophrenia models.", "Brennan, M. et al. (2014). Pharmacogenetics of second-generation antipsychotics.", "Richter, F. et al. (2014). Chronic administration of cholesterol oximes in mice increases transcription of cytoprotective genes and improves transcriptome alterations induced by alpha-synuclein overexpression in nigrostriatal dopaminergic neurons.", "Saung, W. et al. (2014). Lack of influence of DAT1 and DRD2 gene variants on antidepressant response in generalized anxiety disorder.", "Azkona, G. et al. (2014). Sustained increase of PKA activity in the postcommissural putamen of dyskinetic monkeys.", "Lencer, R. et al. (2014). Association of variants in DRD2 and GRM3 with motor and cognitive function in first-episode psychosis.", "Shi, S. et al. (2014). MicroRNA-9 and microRNA-326 regulate human dopamine D2 receptor expression, and the microRNA-mediated expression regulation is altered by a genetic variant.", "Kaplan, N. et al. (2014). Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's disease.", "Ferrero, H. et al. (2014). Dopamine receptor 2 activation inhibits ovarian vascular endothelial growth factor secretion in vitro: implications for treatment of ovarian hyperstimulation syndrome with dopamine receptor 2 agonists.", "Chiesa, A. et al. (2014). Lack of influence of rs4680 (COMT) and rs6276 (DRD2) on diagnosis and clinical outcomes in patients with major depression.", "Herman, A. et al. (2014). Pharmacogenetics of nicotine addiction: role of dopamine.", "Levy, F. et al. (2014). Stimulant side effects: prefrontal/basal ganglia circuit control at dopamine D1/D2 receptors.", "Gold, M. et al. (2014). Low dopamine function in attention deficit/hyperactivity disorder: should genotyping signify early diagnosis in children?", "Berardis, D. et al. (2014). Treatment of antipsychotic-induced hyperprolactinemia: an update on the role of the dopaminergic receptors D2 partial agonist aripiprazole.", "Tashiro, M. et al. (2014). Impact of genetic and non-genetic factors on clinical responses to prochlorperazine in oxycodone-treated cancer patients.", "Basara, N. et al. (2013). Association of dopamine receptor gene polymorphism and psychological personality traits in liability for opioid addiction.", "Zivkovic, M. et al. (2013). The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol.", "Lako, I. et al. (2013). Estimating dopamine D(2) receptor occupancy for doses of 8 antipsychotics: a meta-analysis.", "Moriguchi, S. et al. (2013). Estimated dopamine D(2) receptor occupancy and remission in schizophrenia: analysis of the CATIE data.", "Gomeni, R. et al. (2013). A model-based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP-7000, a new, long-acting, sustained-released formulation of risperidone.", "Rodriguez, R. et al. (2013). Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers.", "McCracken, J. et al. (2014). Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders.", "Roke, Y. et al. (2013). The effect of the Taq1A variant in the dopamine D(2) receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys.", "Clarke, W. et al. (2013). Signalling profile differences: paliperidone versus risperidone.", "Viviani, R. et al. (2014). Use of magnetic resonance imaging in pharmacogenomics.", "Athanasoulia, A. et al. (2014). The effect of the ANKK1/DRD2 Taq1A polymorphism on weight changes of dopaminergic treatment in prolactinomas.", "Spellicy, C. et al. (2013). ANKK1 and DRD2 pharmacogenetics of disulfiram treatment for cocaine abuse.", "Knol, W. et al. (2013). Genetic variation and the risk of haloperidol-related parkinsonism in elderly patients: a candidate gene approach.", "Agundez, J. et al. (2013). Anti-Parkinson's disease drugs and pharmacogenetic considerations.", "Cabaleiro, T. et al. (2013). Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects.", "Domschke, K. et al. (2013). Clinical and molecular genetics of psychotic depression.", "Mallakh, R. et al. (2013). The dopamine D4/D2 receptor antagonist affinity ratio as a predictor of anti-aggression medication efficacy.", "Rominger, A. et al. (2013). Effects of acute detoxification of the herbal blend 'Spice Gold' on dopamine D2/3 receptor availability: a [18F]fallypride PET study.", "Kwak, Y. et al. (2013). Task-dependent interactions between dopamine D2 receptor polymorphisms and L-DOPA in patients with Parkinson's disease.", "Petersson, K. et al. (2013). Predictions of in vivo prolactin levels from in vitro K(i) values of D(2) receptor antagonists using an agonist-antagonist interaction model.", "Utsumi, H. et al. (2013). Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.", "Llerena, A. et al. (2013). Pharmacogenetics of clinical response to risperidone.", "Hart, A. et al. (2013). Candidate gene studies of a promising intermediate phenotype: failure to replicate.", "Isaza, C. et al. (2013). Genetic variants associated with addictive behavior in Colombian addicted and non-addicted to heroin or cocaine.", "Cormier, F. et al. (2013). Genetics of impulse control disorders in Parkinson's disease.", "Luijten, M. et al. (2013). The role of dopamine in inhibitory control in smokers and non-smokers: a pharmacological fMRI study.", "Freeman, T. et al. (2013). Dopaminergic involvement in effort-based but not impulsive reward processing in smokers.", "Rieck, M. et al. (2012). DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson's disease patients.", "Lawford, B. et al. (2013). DRD2/ANKK1 Taq1A (rs 1800497 C>T) genotypes are associated with susceptibility to second generation antipsychotic-induced akathisia.", "Nagai, G. et al. (2012). Prolactin concentrations during aripiprazole treatment in relation to sex, plasma drugs concentrations and genetic polymorphisms of dopamine D2 receptor and cytochrome P450 2D6 in Japanese patients with schizophrenia.", "Houston, J. et al. (2012). Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.", "Tashkin, D. et al. (2012). Association of dopamine-related gene alleles, smoking behavior and decline in FEV1 in subjects with COPD: findings from the lung health study.", "Giegling, I. et al. (2013). Influence of ANKK1 and DRD2 polymorphisms in response to haloperidol.", "Lv, H. et al. (2012). Effects of ningdong granule on DA, DRD2, and HVA in a rat model of Tourette's syndrome.", "Tybura, P. et al. (2012). Some dopaminergic genes polymorphisms are not associated with response to antipsychotic drugs in schizophrenic patients.", "Wang, Y. et al. (2012). The role of single nucleotide polymorphism of D2 dopamine receptor gene on major depressive disorder and response to antidepressant treatment.", "Lee, S. et al. (2012). Association study of 27 annotated genes for clozapine pharmacogenetics: validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response.", "Parkman, H. et al. (2012). Clinical response and side effects of metoclopramide: associations with clinical, demographic, and pharmacogenetic parameters.", "Bakker, P. et al. (2012). Candidate gene-based association study of antipsychotic-induced movement disorders in long-stay psychiatric patients: a prospective study.", "Bloemen, O. et al. (2013). Striatal dopamine D2/3 receptor binding following dopamine depletion in subjects at Ultra High Risk for psychosis.", "Zahari, Z. et al. (2011). A Nested Allele-Specific Multiplex Polymerase Chain Reaction Method for the Detection of DRD2 Polymorphisms.", "Strecker, K. et al. (2012). The 5-HT1A-receptor agonist flibanserin reduces drug-induced dyskinesia in RGS9-deficient mice.", "Tan, H. et al. (2012). Effective connectivity of AKT1-mediated dopaminergic working memory networks and pharmacogenetics of anti-dopaminergic treatment.", "Vulink, N. et al. (2012). Catechol-O-methyltranferase gene expression is associated with response to citalopram in obsessive-compulsive disorder.", "Vehof, J. et al. (2012). Clinical response to antipsychotic drug treatment: association study of polymorphisms in six candidate genes.", "Kim, S. et al. (2012). Neuropathology markers and pathways associated with molecular targets for antipsychotic drugs in postmortem brain tissues: exploration of drug targets through the Stanley Neuropathology Integrative Database.", "Tybura, P. et al. (2011). [Associations between candidate genes with schizophrenia susceptibility and the treatment efficiency].", "Lee, S. et al. (2012). The DRD2/ANKK1 gene is associated with response to add-on dextromethorphan treatment in bipolar disorder.", "Sakurai, H. et al. (2013). Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data.", "Suchanecka, A. et al. (2011). [ANKK1 gene in psychiatry].", "Crowley, J. et al. (2012). Genome-wide association mapping of loci for antipsychotic-induced extrapyramidal symptoms in mice.", "Miura, I. et al. (2012). Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia.", "Putnam, D. et al. (2011). Exploring schizophrenia drug-gene interactions through molecular network and pathway modeling.", "Shimazu, S. et al. (2012). Resistance to dopamine agonists in prolactinoma is correlated with reduction of dopamine D2 receptor long isoform mRNA levels.", "Wang, H. et al. (2011). [Effect of Bushen Huoxue Decoction on dopamine D2 receptor in the brain of rats with Parkinson's disease].", "Wilcox, C. et al. (2011). ANKK1/DRD2 locus variants are associated with rimonabant efficacy in aiding smoking cessation: pilot data.", "Rodrigues, A. et al. (2012). Mechanisms of initiation and reversal of drug-seeking behavior induced by prenatal exposure to glucocorticoids.", "Lee, H. et al. (2011). Genetics of tardive dyskinesia.", "Hung, C. et al. (2011). Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients.", "Lett, T. et al. (2012). Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications.", "Rybakowski, J. et al. (2012). Clinical and pathogenic aspects of candidate genes for lithium prophylactic efficacy.", "Furukori, N. et al. (2011). Comparing the influence of dopamine D(2) polymorphisms and plasma drug concentrations on the clinical response to risperidone.", "Ishii, M. et al. (2012). Negative predictors of clinical response to triptans in patients with migraine.", "DiNieri, J. et al. (2011). Maternal cannabis use alters ventral striatal dopamine D2 gene regulation in the offspring.", "Koning, J. et al. (2012). Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients.", "Zhang, X. et al. (2011). Sexual dysfunction in male schizophrenia: influence of antipsychotic drugs, prolactin and polymorphisms of the dopamine D2 receptor genes.", "Xu, Z. et al. (2011). Influence and interaction of genetic polymorphisms in catecholamine neurotransmitter systems and early life stress on antidepressant drug response.", "Teh, L. et al. (2012). Tridimensional personalities and polymorphism of dopamine D2 receptor among heroin addicts.", "Jain, M. et al. (2012). A cooperative interaction between LPHN3 and 11q doubles the risk for ADHD.", "Weenen, J. et al. (2011). Pharmacological modulation of dopamine receptor D2-mediated transmission alters the metabolic phenotype of diet induced obese and diet resistant C57Bl6 mice.", "Zhu, X. et al. (2011). Stress-induced depressive behaviors are correlated with Par-4 and DRD2 expression in rat striatum.", "Kordas, K. et al. (2011). A dopamine receptor (DRD2) but not dopamine transporter (DAT1) gene polymorphism is associated with neurocognitive development of Mexican preschool children with lead exposure.", "Laugsand, E. et al. (2011). Clinical and genetic factors associated with nausea and vomiting in cancer patients receiving opioids.", "Recouvreux, M. et al. (2011). Active and total transforming growth factor-beta1 are differentially regulated by dopamine and estradiol in the pituitary.", "Guzey, C. et al. (2011). Allele and genotype frequencies of serotonin and dopamine transporter and receptor polymorphisms in a Norwegian population.", "Luque, G. et al. (2011). Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas.", "Klepstad, P. et al. (2011). Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients.", "Hwang, R. et al. (2011). Gene-gene interaction analyses between NMDA receptor subunit and dopamine receptor gene variants and clozapine response.", "Lawford, B. et al. (2012). Alcohol Use Disorders Identification Test (AUDIT) scores are elevated in antipsychotic-induced hyperprolactinaemia.", "Zahari, Z. et al. (2011). Influence of DRD2 polymorphisms on the clinical outcomes of patients with schizophrenia.", "Blasi, G. et al. (2011). DRD2/AKT1 interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in schizophrenia.", "Lai, I. et al. (2011). Analysis of genetic variations in the dopamine D1 receptor (DRD1) gene and antipsychotics-induced tardive dyskinesia in schizophrenia.", "McClay, J. et al. (2011). Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia.", "Houston, J. et al. (2011). Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women.", "Miller, D. et al. (2010). Acute intravenous synaptamine complex variant KB220 \"normalizes\" neurological dysregulation in patients during protracted abstinence from alcohol and opiates as observed using quantitative electroencephalographic and genetic analysis for reward polymorphisms: part 1, pilot study with 2 case reports.", "Parkman, H. et al. (2011). Domperidone treatment for gastroparesis: demographic and pharmacogenetic characterization of clinical efficacy and side-effects.", "Weenen, J. et al. (2011). Blocking dopamine D2 receptors by haloperidol curtails the beneficial impact of calorie restriction on the metabolic phenotype of high-fat diet induced obese mice.", "Lee, J. et al. (2011). Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson's disease.", "Shiroma, P. et al. (2010). Pharmacogenomic implications of variants of monoaminergic-related genes in geriatric psychiatry.", "Brousse, G. et al. (2010). Could the inter-individual variability in cocaine-induced psychotic effects influence the development of cocaine addiction? Towards a new pharmacogenetic approach to addictions.", "Muller, D. et al. (2012). Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain.", "Ruyck, K. et al. (2010). Genetic variation in three candidate genes and nicotine dependence, withdrawal and smoking cessation in hospitalized patients.", "Lencz, T. et al. (2010). DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia.", "Maestre, E. et al. (2010). Identification and quantification of dopamine receptor 2 in human eutopic and ectopic endometrium: a novel molecular target for endometriosis therapy.", "Terrazzino, S. et al. (2010). The serotonin transporter gene polymorphism STin2 VNTR confers an increased risk of inconsistent response to triptans in migraine patients.", "Palma, G. et al. (2010). A case-control study of Parkinson's disease and tobacco use: gene-tobacco interactions.", "Hong, C. et al. (2010). Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment.", "Breitling, L. et al. (2010). Prospective association of dopamine-related polymorphisms with smoking cessation in general care.", "Zivkovic, M. et al. (2010). The role of CYP2D6 and TaqI A polymorphisms in malignant neuroleptic syndrome: two case reports with three episodes.", "Zhang, J. et al. (2010). D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis.", "Sangrajrang, S. et al. (2010). Genetic polymorphisms in folate and alcohol metabolism and breast cancer risk: a case-control study in Thai women.", "Lencz, T. et al. (2009). Pharmacogenetics of antipsychotic-induced side effects.", "Smith, H. et al. (2010). The role of genomic oxidative-reductive balance as predictor of complex regional pain syndrome development: a novel theory.", "Stefan, P. et al. (2009). Development of a high-throughput method for screening the dopamine D2 (DRD2) receptor gene polymorphisms based on the LightCycler system.", "Dusitanond, P. et al. (2009). Neuroleptics and migraine.", "Correia, C. et al. (2010). Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions.", "Hamidovic, A. et al. (2009). Evaluation of genetic variability in the dopamine receptor D2 in relation to behavioral inhibition and impulsivity/sensation seeking: an exploratory study with d-amphetamine in healthy participants.", "Blum, K. et al. (2009). Neurogenetics of dopaminergic receptor supersensitivity in activation of brain reward circuitry and relapse: proposing \"deprivation-amplification relapse therapy\" (DART).", "Filopanti, M. et al. (2010). Pharmacogenetics of D2 dopamine receptor gene in prolactin-secreting pituitary adenomas.", "Houston, J. et al. (2010). Genetic associations of prolactin increase in olanzapine/fluoxetine combination-treated patients.", "Arbouw, M. et al. (2009). Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson's disease.", "Manchia, M. et al. (2009). No association between lithium full responders and the DRD1, DRD2, DRD3, DAT1, 5-HTTLPR and HTR2A genes in a Sardinian sample.", "Lotsch, J. et al. (2009). Genetic modulation of the pharmacological treatment of pain.", "Ooteman, W. et al. (2009). Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators.", "Gasso, P. et al. (2009). A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms.", "Bergen, A. et al. (2009). Dopamine genes and nicotine dependence in treatment-seeking and community smokers.", "Gilbert, D. et al. (2009). Neurotransmission-related genetic polymorphisms, negative affectivity traits, and gender predict tobacco abstinence symptoms across 44 days with and without nicotine patch.", "Liu, Y. et al. (2009). Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson's disease patients.", "Leddy, J. et al. (2009). Dopamine-related genotypes and the dose-response effect of methylphenidate on eating in attention-deficit/hyperactivity disorder youths.", "Calarge, C. et al. (2009). Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents.", "Chen, S. et al. (2009). Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors.", "Ujike, H. et al. (2009). Genetic variants of D2 but not D3 or D4 dopamine receptor gene are associated with rapid onset and poor prognosis of methamphetamine psychosis.", "Zai, C. et al. (2009). Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients.", "Duric, G. et al. (2009). [Dopa-responsive dystonia].", "Hadithy, A. et al. (2009). Lack of association between antipsychotic-induced Parkinsonism or its subsymptoms and rs4606 SNP of RGS2 gene in African-Caribbeans and the possible role of the medication: the Curacao extrapyramidal syndromes study X.", "Mukda, S. et al. (2009). Amphetamine-induced changes in dopamine receptors in early postnatal rat brain.", "Liou, Y. et al. (2008). The coding-synonymous polymorphism rs1045280 (Ser280Ser) in beta-arrestin 2 (ARRB2) gene is associated with tardive dyskinesia in Chinese patients with schizophrenia.", "Shen, Y. et al. (2009). Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients.", "Lafuente, A. et al. (2008). Polymorphism of dopamine D2 receptor (TaqIA, TaqIB, and-141C Ins/Del) and dopamine degradation enzyme (COMT G158A, A-278G) genes and extrapyramidal symptoms in patients with schizophrenia and bipolar disorders.", "Ikeda, M. et al. (2008). Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia.", "Zai, C. et al. (2008). Genetic study of eight AKT1 gene polymorphisms and their interaction with DRD2 gene polymorphisms in tardive dyskinesia.", "Passos, V. et al. (2009). Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists.", "Kwon, J. et al. (2008). Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole.", "Thelma, B. et al. (2008). Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics.", "Blum, K. et al. (2008). LG839: anti-obesity effects and polymorphic gene correlates of reward deficiency syndrome.", "Johnson, A. et al. (2008). Polymorphisms affecting gene transcription and mRNA processing in pharmacogenetic candidate genes: detection through allelic expression imbalance in human target tissues.", "Crettol, S. et al. (2008). Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment.", "Saveanu, A. et al. (2009). Somatostatin-dopamine ligands in the treatment of pituitary adenomas.", "Drtilkova, I. et al. (2008). Clinical and molecular-genetic markers of ADHD in children.", "Furukori, N. et al. (2008). Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients.", "Florez, G. et al. (2008). Association between the Stin2 VNTR polymorphism of the serotonin transporter gene and treatment outcome in alcohol-dependent patients.", "Kohlrausch, F. et al. (2008). Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics.", "Bialecka, M. et al. (2008). [Pharmacogenetics in Parkinson's disease treatment].", "Kang, S. et al. (2008). Association study between antipsychotics- induced restless legs syndrome and polymorphisms of dopamine D1, D2, D3, and D4 receptor genes in schizophrenia.", "Leon, J. et al. (2008). A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics: part I.", "Hadithy, A. et al. (2008). Pharmacogenetics of parkinsonism, rigidity, rest tremor, and bradykinesia in African-Caribbean inpatients: differences in association with dopamine and serotonin receptors.", "Filopanti, M. et al. (2008). Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas.", "Bakker, P. et al. (2008). Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions.", "Paus, S. et al. (2008). The DRD2 TaqIA polymorphism and demand of dopaminergic medication in Parkinson's disease.", "Alenius, M. et al. (2008). Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting.", "Aklillu, E. et al. (2007). CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine.", "David, S. et al. (2007). Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials.", "Yao, Y. et al. (2008). Verification of proposed peripheral biomarkers in mononuclear cells of individuals with schizophrenia.", "David, S. et al. (2007). Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation.", "Asuni, C. et al. (2007). Association study between clinical response to rizatriptan and some candidate genes.", "Swan, G. et al. (2007). Joint effect of dopaminergic genes on likelihood of smoking following treatment with bupropion SR.", "Blum, K. et al. (2007). Manipulation of catechol-O-methyl-transferase (COMT) activity to influence the attenuation of substance seeking behavior, a subtype of Reward Deficiency Syndrome (RDS), is dependent upon gene polymorphisms: a hypothesis.", "Dolzan, V. et al. (2007). Polymorphisms in dopamine receptor DRD1 and DRD2 genes and psychopathological and extrapyramidal symptoms in patients on long-term antipsychotic treatment.", "Vandenbergh, D. et al. (2007). Dopamine receptor genes (DRD2, DRD3 and DRD4) and gene-gene interactions associated with smoking-related behaviors.", "Sakumoto, N. et al. (2007). Dopamine D2 receptor gene polymorphisms predict well the response to dopamine antagonists at therapeutic dosages in patients with schizophrenia.", "Guzey, C. et al. (2007). Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms.", "Robinson, J. et al. (2007). The DRD2 TaqI-B polymorphism and its relationship to smoking abstinence and withdrawal symptoms.", "Hu, J. et al. (2006). No evidence for a major role of polymorphisms during bupropion treatment.", "Xing, Q. et al. (2007). The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients.", "Gunes, A. et al. (2007). Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients.", "Zai, C. et al. (2007). Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients.", "Wu, S. et al. (2006). Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients.", "Connor, J. et al. (2007). Heavy nicotine and alcohol use in alcohol dependence is associated with D2 dopamine receptor (DRD2) polymorphism.", "Anderson, G. et al. (2007). Effects of short- and long-term risperidone treatment on prolactin levels in children with autism.", "Hedenmalm, K. et al. (2006). Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms.", "Barratt, D. et al. (2006). Association between the DRD2 A1 allele and response to methadone and buprenorphine maintenance treatments.", "Lencz, T. et al. (2006). DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients.", "Leon, J. et al. (2005). Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness.", "Lerman, C. et al. (2006). Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials.", "Nakazono, Y. et al. (2005). Association between neuroleptic drug-induced extrapyramidal symptoms and dopamine D2-receptor polymorphisms in Japanese schizophrenic patients.", "Abdolmaleky, H. et al. (2005). Genetics and epigenetics in major psychiatric disorders: dilemmas, achievements, applications, and future scope.", "Lane, H. et al. (2005). Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics.", "Zappia, M. et al. (2005). Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study.", "Wu, S. et al. (2005). Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients.", "Tsai, S. et al. (2004). Dopamine receptor downregulation: an alternative strategy for schizophrenia treatment.", "Swan, G. et al. (2005). Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR.", "Zhang, L. et al. (2004). [Molecular pharmacogenetic studies of drug responses to obsessive-compulsive disorder and six functional genes].", "Lattuada, E. et al. (2004). Tardive dyskinesia and DRD2, DRD3, DRD4, 5-HT2A variants in schizophrenia: an association study with repeated assessment.", "Scharfetter, J. et al. (2004). Pharmacogenetics of dopamine receptors and response to antipsychotic drugs in schizophrenia--an update.", "Young, R. et al. (2004). Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele.", "Serretti, A. et al. (2004). Genetic features of antidepressant induced mania and hypo-mania in bipolar disorder.", "Epstein, L. et al. (2004). Relation between food reinforcement and dopamine genotypes and its effect on food intake in smokers.", "Cinciripini, P. et al. (2004). The effects of the DRD2 polymorphism on smoking cessation and negative affect: evidence for a pharmacogenetic effect on mood.", "Malhotra, A. et al. (2004). Candidate gene studies of antipsychotic drug efficacy and drug-induced weight gain.", "Lane, H. et al. (2004). Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function.", "Lerman, C. et al. (2004). Changes in food reward following smoking cessation: a pharmacogenetic investigation.", "Johnstone, E. et al. (2004). Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch.", "David, S. et al. (2003). Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome?", "Yamanouchi, Y. et al. (2003). Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone.", "Segman, R. et al. (2003). Association of dopaminergic and serotonergic genes with tardive dyskinesia in patients with chronic schizophrenia.", "Landi, S. et al. (2003). Evaluation of a microarray for genotyping polymorphisms related to xenobiotic metabolism and DNA repair.", "Lerman, C. et al. (2003). Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial.", "Kondo, T. et al. (2003). Combination of dopamine D2 receptor gene polymorphisms as a possible predictor of treatment-resistance to dopamine antagonists in schizophrenic patients.", "Lawford, B. et al. (2003). D2 dopamine receptor gene polymorphism: paroxetine and social functioning in posttraumatic stress disorder.", "Severino, G. et al. (2003). Pharmacogenomics: state of the research and perspectives in clinical application.", "Kaiser, R. et al. (2003). L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism.", "Zhang, Z. et al. (2003). [Pharmacogenetic assessment of antipsychotic-induced tardive dyskinesia: contribution of 5-hydroxytryptamine 2C receptor gene and of a combination of dopamine D3 variant allele (Gly) and MnSOD wild allele (Val)].", "Zhang, Z. et al. (2003). No association of antipsychotic agent-induced weight gain with a DA receptor gene polymorphism and therapeutic response.", "Kishida, I. et al. (2003). Lack of association in Japanese patients between neuroleptic malignant syndrome and the TaqI A polymorphism of the dopamine D2 receptor gene.", "Chong, S. et al. (2003). Polymorphisms of dopamine receptors and tardive dyskinesia among Chinese patients with schizophrenia.", "Qi, J. et al. (2002). [Study on the association between smoking behavior and dopamine receptor D2 gene polymorphisms among lung cancer cases].", "Kaiser, R. et al. (2002). Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia.", "Morimoto, K. et al. (2002). Delusional disorder: molecular genetic evidence for dopamine psychosis.", "Serretti, A. et al. (2001). No association between dopamine D(2) and D(4) receptor gene variants and antidepressant activity of two selective serotonin reuptake inhibitors.", "Lucht, M. et al. (2001). Influence of the dopamine D2 receptor (DRD2) exon 8 genotype on efficacy of tiapride and clinical outcome of alcohol withdrawal.", "Suzuki, A. et al. (2001). Association of the TaqI A polymorphism of the dopamine D(2) receptor gene with predisposition to neuroleptic malignant syndrome.", "Suzuki, A. et al. (2001). The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients.", "Suzuki, A. et al. (2001). Association between TaqI A dopamine D2 receptor polymorphism and therapeutic response to bromperidol: a preliminary report.", "Mihara, K. et al. (2001). Relationship between Taq1 A dopamine D2 receptor (DRD2) polymorphism and prolactin response to bromperidol.", "Berlin, I. et al. (2000). Dopaminergic drug response and the genotype (Taq IA polymorphism) of the dopamine D2 receptor.", "Schafer, M. et al. (2001). Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene.", "Mihara, K. et al. (2001). No relationship between--141C Ins/Del polymorphism in the promoter region of dopamine D2 receptor and extrapyramidal adverse effects of selective dopamine D2 antagonists in schizophrenic patients: a preliminary study.", "Buck, K. et al. (2000). Mapping quantitative trait loci that regulate sensitivity and tolerance to quinpirole, a dopamine mimetic selective for D(2)/D(3) receptors.", "Lawford, B. et al. (2000). The D(2) dopamine receptor A(1) allele and opioid dependence: association with heroin use and response to methadone treatment.", "Piovesan, E. et al. (2000). [Change in the biological pattern of migraine with aura after the use of tetrabenazine: case report].", "Mihara, K. et al. (2000). No relationship between Taq1 a polymorphism of dopamine D(2) receptor gene and extrapyramidal adverse effects of selective dopamine D(2) antagonists, bromperidol, and nemonapride in schizophrenia: a preliminary study.", "Suzuki, A. et al. (2000). The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients.", "Mihara, K. et al. (2000). Prolactin response to nemonapride, a selective antagonist for D2 like dopamine receptors, in schizophrenic patients in relation to Taq1A polymorphism of DRD2 gene.", "Makoff, A. et al. (2000). Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease.", "Winsberg, B. et al. (1999). Association of the dopamine transporter gene (DAT1) with poor methylphenidate response.", "Serretti, A. et al. (1999). Dopamine receptor D2 and D4 genes, GABA(A) alpha-1 subunit genes and response to lithium prophylaxis in mood disorders.", "Cravchik, A. et al. (1999). Analysis of neuroleptic binding affinities and potencies for the different human D2 dopamine receptor missense variants.", "Singleton, A. et al. (1998). Lack of association between the dopamine D2 receptor gene allele DRD2*A1 and cigarette smoking in a United Kingdom population.", "Mascia, A. et al. (1998). Dopamine and migraine: a review of pharmacological, biochemical, neurophysiological, and therapeutic data.", "Thompson, J. et al. (1997). D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele.", "Finckh, U. et al. (1997). Influence of the dopamine D2 receptor (DRD2) genotype on neuroadaptive effects of alcohol and the clinical outcome of alcoholism.", "Peroutka, S. et al. (1997). Clinical susceptibility to migraine with aura is modified by dopamine D2 receptor (DRD2) NcoI alleles.", "Blum, K. et al. (1996). Increased prevalence of the Taq I A1 allele of the dopamine receptor gene (DRD2) in obesity with comorbid substance use disorder: a preliminary report.", "Comings, D. et al. (1996). A study of the dopamine D2 receptor gene in pathological gambling.", "Comings, D. et al. (1996). The dopamine D2 receptor (DRD2) gene: a genetic risk factor in smoking.", "Blum, K. et al. (1995). Dopamine D2 receptor gene variants: association and linkage studies in impulsive-addictive-compulsive behaviour.", "Lawford, B. et al. (1995). Bromocriptine in the treatment of alcoholics with the D2 dopamine receptor A1 allele.", "Blum, K. et al. (1994). Prolonged P300 latency in a neuropsychiatric population with the D2 dopamine receptor A1 allele."]